A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada (vol 19, pg 78, 2012)

被引：0
|
作者：
Hirsh, V.
Melosky, B.
Goss, G.
Morris, D.
Morzycki, W.
机构：
来源：
CURRENT ONCOLOGY | 2012年 / 19卷 / 03期
关键词：
D O I：
10.3747/co.19.1150
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E228 / E228
页数：1
相关论文
共 50 条
  • [1] A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada
    Hirsh, V.
    Melosky, B.
    Goss, G.
    Morris, D.
    Morzycki, W.
    [J]. CURRENT ONCOLOGY, 2012, 19 (02) : 78 - 90
  • [2] EGFR tyrosine kinase mutation testing in the treatment of non-small-cell lung cancer
    Kamel-Reid, S.
    Chong, G.
    Ionescu, D. N.
    Magliocco, A. M.
    Spatz, A.
    Tsao, M.
    Weng, X.
    Young, S.
    Zhang, T.
    Soulieres, D.
    [J]. CURRENT ONCOLOGY, 2012, 19 (02) : E67 - E74
  • [3] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    [J]. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [4] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    [J]. Current Treatment Options in Oncology, 2016, 17
  • [5] Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Clash of the Generations
    Shah, Riyaz
    Lester, Jason F.
    [J]. CLINICAL LUNG CANCER, 2020, 21 (03) : E216 - E228
  • [6] The role of EGFR tyrosine kinase inhibitors in the treatment of non-small cell lung cancer
    Kowalczyk, Anna
    Szutowicz-Zielinska, Ewa
    Dziadziuszko, Rafal
    Jassem, Jacek
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (04): : 217 - 224
  • [7] EGFR tyrosine kinase inhibitors in the treatment of advanced non-small cell lung cancer
    Kowalski, D. M.
    Krzakowski, M.
    Jaskiewicz, P.
    Janowicz-Zebrowska, A.
    Glogowski, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] INCIDENCE OF HEPATITIS B REACTIVATION DURING EGFR TYROSINE KINASE INHIBITORS TREATMENT IN NON-SMALL-CELL LUNG CANCER PATIENTS
    Yao, Zong-Han
    Liao, Wei-Yu
    Ho, Chao-Chi
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Chen, Jin-Shing
    Lin, Zhong-Zhe
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    [J]. RESPIROLOGY, 2018, 23 : 291 - 291
  • [9] Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Pitini, Vincenzo
    Rosell, Rafael
    [J]. FUTURE ONCOLOGY, 2015, 11 (08) : 1259 - 1274
  • [10] Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?
    Passaro, Antonio
    Cortesi, Enrico
    de Marinis, Filippo
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (10) : 1587 - 1597
12345